Facilitated By

San Antonio Medical Foundation

A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial Of Emricasan (Idn-6556), An Oral Caspase Inhibitor, In Subjects With Non-Alcoholic Steatohepatitis (Nash) Fibrosis

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active

This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of definite NASH with fibrosis (excluding cirrhosis) as determined by the central histopathologist. Upon successful screening, subjects will be randomized to receive emricasan 50 mg BID, emricasan 5 mg BID or placebo BID.

Clinical Care
Infectious Disease
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.